His research interests include the development and application of Bayesian methods in drug development. He has particular expertise in evidence synthesis and survival analysis in submissions to the National Institute for Health and Care Excellence (NICE). He is a member of the ScHARR Technology Assessment Group Management Team and has served on the NICE Appraisal Committee.
Prior to joining academia, John spent 25 years working as a statistician in the pharmaceutical industry across all phases of drug development and a variety of therapeutic areas. It was while at AstraZeneca that John developed an interest in Bayesian statistics, including decision-theoretic dose-escalation, sample size calculation and health economics.